2023
Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848
Tchelebi L, Winter K, Abrams R, Safran H, Regine W, McNulty S, Wu A, Du K, Seaward S, Bian S, Aljumaily R, Shivnani A, Knoble J, Crocenzi T, DiPetrillo T, Roof K, Crane C, Goodman K. Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848. International Journal Of Radiation Oncology • Biology • Physics 2023, 118: 107-114. PMID: 37598723, PMCID: PMC10843017, DOI: 10.1016/j.ijrobp.2023.08.014.Peer-Reviewed Original ResearchConceptsTarget volumeRadiation therapy quality assuranceRadiation therapyPlanning target volumeClinical treatment volumeGross target volumePretreatment QAContouring atlasTreatment planningResectable pancreatic head adenocarcinomaRT planningIntensity modulated RTQA analysisPancreatic head adenocarcinomaNRG Oncology RTOGPracticing radiation oncologistsReal-time quality assuranceTreatment volumeEffects of RTConcurrent fluoropyrimidineConformal RTAdjuvant chemotherapyRadiation oncologistsQuality assurancePancreas cancer
2020
A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Wu J, Atkinson E, Leichman L, Patel H, Iqbal S, Du K, Bizekis C, Goldberg J, Thomas C, Cohen D, Becker D, Siolas D, Beri N, Oberstein P, Ku G. A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Journal Of Clinical Oncology 2020, 38: 372-372. DOI: 10.1200/jco.2020.38.4_suppl.372.Peer-Reviewed Original ResearchEsophageal squamous cell carcinomaAdvanced esophageal squamous cell carcinomaClinical CRRadiation therapyPhase I/II studyCarboplatin/paclitaxelEfficacy of nivolumabGrade 2 esophagitisGrade 3/4 AEsGrade 5 toxicityOverall survival benefitPhase II portionSquamous cell carcinomaConcurrent chemoRTManageable toxicityLast dosePrimary endpointII studyUnacceptable toxicityElevated ASTSurvival benefitCell carcinomaChemoRTGrade 3Nivolumab
2018
A phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Giuroiu I, Ku G, Leichman L, Du K, Oh P, Levinson B, Iqbal S, Thomas C, Wu J. A phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC). Journal Of Clinical Oncology 2018, 36: tps199-tps199. DOI: 10.1200/jco.2018.36.4_suppl.tps199.Peer-Reviewed Original ResearchEsophageal squamous cell carcinomaAdvanced esophageal squamous cell carcinomaPathologic complete responseOverall survivalClinical CRRadiation therapyMedian progression-free survivalPhase IEfficacy of nivolumabCarboplatin/paclitaxelOverall survival benefitProgression-free survivalKaplan-Meier curvesSquamous cell carcinomaMulti-center studyLast dosePrimary endpointUnacceptable toxicitySurvival benefitComplete responseMeier curvesAbscopal effectCell carcinomaExtensive tumorsEsophageal cancer
2016
Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice
Seifert L, Werba G, Tiwari S, Ly N, Nguy S, Alothman S, Alqunaibit D, Avanzi A, Daley D, Barilla R, Tippens D, Torres-Hernandez A, Hundeyin M, Mani VR, Hajdu C, Pellicciotta I, Oh P, Du K, Miller G. Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice. Gastroenterology 2016, 150: 1659-1672.e5. PMID: 26946344, PMCID: PMC4909514, DOI: 10.1053/j.gastro.2016.02.070.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaImmune suppressive phenotypeT cell responsesRadiation therapyT cellsTumor growthControl micePancreatic tumorsT cell-mediated anti-tumor responsesAdvanced unresectable pancreatic ductal adenocarcinomaAnti-tumor T cell responsesInvasive pancreatic ductal adenocarcinomaSuppress T cell responsesUnresectable pancreatic ductal adenocarcinomaMurine pancreatic ductal adenocarcinomaPancreatic intraepithelial lesionsAnti-tumor responseT helper 2Treatment of patientsRegulatory cell phenotypeM2-like phenotypePhenotype of macrophagesAdoptive transferKC miceUnexposed mice
2015
Anal Cancer Outcomes in Patients Treated With Intensity Modulated Compared to 3-Dimensional Radiation Therapy
Cooper B, Bitterman D, Grew D, No H, Sanfilippo N, Du K. Anal Cancer Outcomes in Patients Treated With Intensity Modulated Compared to 3-Dimensional Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e165. DOI: 10.1016/j.ijrobp.2015.07.972.Peer-Reviewed Original ResearchDosimetric Comparison of Proton Therapy, Volumetric Modulated Arc Therapy, and 3-D Conformal Radiation Therapy for the Treatment of Rectal Cancer: An Early Community Experience
Cooper B, Qu J, Chon B, Tsai H, Mah D, Du K, DeWyngaert J, Yeh B. Dosimetric Comparison of Proton Therapy, Volumetric Modulated Arc Therapy, and 3-D Conformal Radiation Therapy for the Treatment of Rectal Cancer: An Early Community Experience. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e176. DOI: 10.1016/j.ijrobp.2015.07.999.Peer-Reviewed Original ResearchRadiation Therapy Induces an Immunosuppressive Immune Infiltrate in a Murine Model of Invasive Pancreatic Cancer
Nguy S, Tomkoetter L, Alothman S, Alqunaibit D, Miller G, Du K. Radiation Therapy Induces an Immunosuppressive Immune Infiltrate in a Murine Model of Invasive Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: s95-s96. DOI: 10.1016/j.ijrobp.2015.07.229.Peer-Reviewed Original ResearchComparison of anal cancer outcomes in public and private hospital patients treated at a single radiation oncology center
Bitterman DS, Grew D, Gu P, Cohen RF, Sanfilippo NJ, Leichman CG, Leichman LP, Moore HG, Gold HT, Du KL. Comparison of anal cancer outcomes in public and private hospital patients treated at a single radiation oncology center. Journal Of Gastrointestinal Oncology 2015, 6: 524-33. PMID: 26487947, PMCID: PMC4570920, DOI: 10.3978/j.issn.2078-6891.2015.061.Peer-Reviewed Original ResearchDisease-free survivalColostomy-free survivalOverall survivalPublic hospital patientsPrivate hospital patientsHospital patientsRadiotherapy durationFree survivalRadiotherapy delayRadiation therapyHigher clinical T stageThree-year overall survivalPoor disease-free survivalPrivate hospitalsAdvanced anal cancerAnal cancer outcomesSame cancer centerUnplanned treatment breaksClinical T stageAnal cancer patientsKaplan-Meier methodLow socioeconomic status populationClinical stage groupsLog-rank testProportional hazards modelRadiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data
Modrek AS, Hsu HC, Leichman CG, Du KL. Radiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data. Radiation Oncology 2015, 10: 101. PMID: 25902707, PMCID: PMC4464878, DOI: 10.1186/s13014-015-0411-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, AlkylatingAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Small CellCombined Modality TherapyDigestive System Surgical ProceduresFemaleHumansKaplan-Meier EstimateMaleMiddle AgedOrganoplatinum CompoundsProportional Hazards ModelsRectal NeoplasmsRetrospective StudiesSEER ProgramSurvival AnalysisUnited StatesConceptsRadiation therapyOverall survivalRectal cancerSurveillance EpidemiologyCell carcinomaSEER dataMultivariate Cox proportional hazards modelCox proportional hazards modelBackgroundSmall cell carcinomaMethodsThe SEER databaseCancer-directed therapyEnd Results (SEER) databaseUnadjusted hazard ratioEnd Results (SEER) dataKaplan-Meier methodOverall survival rateYear of diagnosisSmall cell carcinomaSignificant survival advantagePearson's chi-square testProportional hazards modelOnly significant factorChi-square testChemotherapy usageLocoregional casesAnal cancer outcomes in patients treated with intensity modulated versus 3-dimensional chemoradiotherapy.
Cooper B, Grew D, Bitterman D, Sanfilippo N, Du K. Anal cancer outcomes in patients treated with intensity modulated versus 3-dimensional chemoradiotherapy. Journal Of Clinical Oncology 2015, 33: 662-662. DOI: 10.1200/jco.2015.33.3_suppl.662.Peer-Reviewed Original ResearchDistant metastasis-free survivalLocal recurrence-free survivalColostomy-free survivalOverall survivalTreatment interruptionLymph nodesTreatment breaksSkin toxicityRadiation therapyThree-year overall survivalAnal cancer outcomesGrowth factor supportRecurrence-free survivalMetastasis-free survivalSquamous cell carcinomaKaplan-Meier survivalConformal radiation therapyRadiation techniquesLog-rank statisticsChi-square testAcute gastrointestinalAcute GIDefinitive chemoradiotherapyIMRT cohortRTOG 0529
2013
Radiation Therapy Improves Survival in Small Cell Rectal Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data
Hsu H, Leichman C, Du K. Radiation Therapy Improves Survival in Small Cell Rectal Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s188. DOI: 10.1016/j.ijrobp.2013.06.484.Peer-Reviewed Original ResearchInhibition of Hsp27 Radiosensitizes Head-and-Neck Cancer by Modulating Deoxyribonucleic Acid Repair
Guttmann DM, Hart L, Du K, Seletsky A, Koumenis C. Inhibition of Hsp27 Radiosensitizes Head-and-Neck Cancer by Modulating Deoxyribonucleic Acid Repair. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: 168-175. PMID: 23849696, DOI: 10.1016/j.ijrobp.2013.05.028.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAtaxia Telangiectasia Mutated ProteinsCell Cycle ProteinsCell Line, TumorDNA RepairDNA, NeoplasmDNA-Binding ProteinsGene Knockdown TechniquesHead and Neck NeoplasmsHistonesHSP27 Heat-Shock ProteinsHumansMiceMice, NudeOligonucleotidesProtein Serine-Threonine KinasesRadiation ToleranceRNA, Small InterferingTumor Suppressor ProteinsConceptsShort hairpin RNANeck cancer cell linesCancer cell linesNeck cancerNude miceTumor growthHsp27 knockdownRadiotherapy of headFractionated radiation therapyFaDu human headEffect of Hsp27Cell linesEffective clinical agentRole of HSP27LNA treatmentFlank tumorsRadiation therapyTumor xenograftsDeoxyribonucleic acid repairTumor radiosensitizationClonogenic survivalClinical agentsHairpin RNAHSP27DNA repair signaling
2010
Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma
Du KL, Both S, Friedberg JS, Rengan R, Hahn SM, Cengel KA. Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma. Cancer Biology & Therapy 2010, 10: 425-429. PMID: 20699634, DOI: 10.4161/cbt.10.5.12616.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaPlanning treatment volumeExtrapleural pneumonectomyPleural mesotheliomaRadiation therapyImproved local controlMedian radiation doseFuture prospective analysesTreatment of mesotheliomaNew treatment modalitiesIntraoperative photodynamic therapyQuality of lifePhotodynamic therapyIntraoperative adjuvantMultimodality therapyRadiation pneumonitisRespiratory failureSurgical debulkingContralateral lungMPM patientsDoses of radiationMechanical ventilationMultimodality approachLung toxicityTreatment modalities